Finding advances search for cure other than liver transplantation
A protein modified to increase the amount of time it circulates in the bloodstream appears to reverse liver fibrosis and cirrhosis in rats, according to results of a study led by Johns Hopkins researchers.
The investigators say the findings, reported ahead of print in the March 3 early view edition of Hepatology, advance the search for a potential cure for the thousands of patients worldwide living with these incurable diseases. At present, there is little effective treatment and no cure other than liver transplantation, which carries its own risks and often fails.
“Our findings demonstrate that the damaging effects of liver cirrhosis in laboratory rats can be effectively treated, and perhaps even reversed, using a protein therapeutic that has been modified to enhance its activity through site-specific conjugation of a polymer that greatly enhances its residence time in the body,” says senior author Justin Hanes, Ph.D., director of the Center for Nanomedicine at the Wilmer Eye Institute at Johns Hopkins. “This approach has tremendous potential to help people with this devastating condition and may also be helpful to the millions of patients with other diseases where fibrosis plays an important role.”
Liver fibrosis and its more severe form, cirrhosis, are caused by scar tissue that forms in the liver that is usually induced by chronic alcohol abuse, infections and autoimmune diseases. The progressive stiffening of the liver, a hallmark of the disorders, occurs when a type of liver cell known as the hepatic stellate cell is “activated” and overproduces the stringy network of proteins called the extracellular matrix that binds cells together.
Being able to turn cirrhosis around, especially in its late stages, would be a great boon, says Seulki Lee, Ph.D., assistant professor in the Department of Radiology and Radiological Science at the Johns Hopkins University School of Medicine. “That’s because liver fibrosis and cirrhosis can be asymptomatic for decades,” Lee says. “Many patients only seek treatment when their disease becomes very advanced, at which point liver transplant is their only option.”
Lee cautions, however, that his team’s work is years from any possible application to patients.
Scientists have known for more than a decade that a protein called tumor necrosis factor-related apoptosis-inducing ligand — TRAIL, for short — can specifically kill activated hepatic stellate cells that overproduce the extracellular matrix, sparing healthy cells in the liver. However, Lee explains, TRAIL has thus far proven unsuccessful for clinical use because in animal studies, enzymes in the bloodstream quickly degrade it before it has time to work.
Seeking a way to extend TRAIL’s half-life, or the time that it remains intact in the bloodstream, Lee and his colleagues coated TRAIL with polyethylene glycol (PEG), a synthetic polymer that’s widely used as a preservative, lubricant and ingredient in skin creams, and is already being used to extend the bloodstream life of a handful of drugs that treat neutropenia, hemophilia and rheumatoid arthritis.
Lee says initial experiments showed that this “PEGylated” TRAIL had a half-life of between eight and nine hours in monkeys, compared to less than 30 minutes for the unmodified protein. When the scientists intravenously dosed rats that had liver fibrosis with the modified TRAIL for 10 days, the animals’ activated hepatic stellate cells died off. By fighting these bad cells, signs of fibrosis began to diminish. Further investigation showed that multiple genes associated with fibrosis had reduced activity, and the proteins produced by these genes faded away.
Findings were similar in rats with advanced cirrhosis, Lee says. Additionally, when the researchers examined the rodents’ liver tissue under a microscope, they found that animals treated with PEGylated TRAIL had fewer deposits of collagen and other extracellular matrix proteins, offering some evidence that the disease had actually been reversed.
Further experiments showed that PEGylated TRAIL selectively killed human-activated hepatic stellate cells growing in petri dishes while leaving normal liver cells unharmed, suggesting that findings in these animal models could apply to damaged human livers with limited toxicity concerns.
Lee says the research team hopes to develop PEGylated TRAIL for clinical trials in human patients in the next two years. He adds that some preliminary data suggest that the modified protein could also treat other fibrotic diseases as well, such as pancreatic or lung fibrosis, which also have no effective treatment.
“Eventually,” Lee says, “we might be able to develop PEGylated TRAIL into a universal anti-fibrotic agent that can treat many different conditions.”
Learn more: Modified protein reverses cirrhosis in lab rats
The Latest on: Protein therapeutic
[google_news title=”” keyword=”Protein therapeutic” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Protein therapeutic
- Dyne Therapeutics gets grant for patent granted for method of reducing DMPK expression in muscleon April 23, 2024 at 5:51 am
Reduce DMPK expression in muscle cells with Dyne Therapeutics' patented method using an anti-transferrin receptor antibody linked to an oligonucleotide. Learn more about this potential treatment for ...
- BioAtla gets grant for patent granted for antibody binding to AXL proteinon April 23, 2024 at 5:49 am
Discover how BioAtla's patented antibody targets Axl protein in cancer treatment. Learn about immunoconjugates, pharmaceutical compositions, and treatment methods covered in the US11897959B2 ...
- Scientists discover the cellular functions of a family of proteins integral to inflammatory diseaseson April 22, 2024 at 12:00 pm
In a scientific breakthrough, Mount Sinai researchers have revealed the biological mechanisms by which a family of proteins known as histone deacetylases (HDACs) activate immune system cells linked to ...
- Windtree Therapeutics is dangerously low on cashon April 22, 2024 at 9:02 am
The Bucks County biotech company told the SEC it only has enough cash to fund operations through the end of this month, but the firm's CEO says it has a plan to remain viable.
- Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)on April 22, 2024 at 6:00 am
Analysts have set 12-month price targets for Kymera Therapeutics, revealing an average target of $53.0, a high estimate of $56.00, and a low estimate of $47.00. Observing a 42.28% increase, the ...
- UMass Amherst Researcher Awarded $936K NIH Grant to Democratize Protein Analysis with Innovative Techon April 19, 2024 at 12:50 pm
UMass Amherst's Sarah Perry secures a $936k NIH grant to develop tech for observing dynamic protein movements.
- Outrun Therapeutics launches to stabilize proteinson April 19, 2024 at 6:23 am
Outrun Therapeutics has launched with $10 million in seed financing. The company spun out of Satpal Virdee’s lab at the University of Dundee and is focused on stabilizing proteins, or keeping ...
- Visual Proteomics: Observing Protein Location in Living Cellson April 19, 2024 at 6:00 am
Proteins function dynamically in cells, and tracking their location precisely in living cells has been a major technical challenge. Current methods involve individually labeling individual proteins ...
- Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancieson April 15, 2024 at 4:29 am
Nurix Therapeutics raises $175 million in an upsized offering after a 168% stock return in the past six months. Read why I'm neutral on NRIX stock.
- Buy Rating Affirmed: Promising Clinical Data and Strategic Shift Bolster Carisma Therapeutics’ Outlookon April 11, 2024 at 10:37 pm
Analyst Jack Allen of Robert W. Baird maintained a Buy rating on Carisma Therapeutics (CARM – Research Report), with a price target of ...
via Bing News